Research programme: cancer diagnostic agents - Sunbird Bio
Latest Information Update: 30 Mar 2026
At a glance
- Originator Glympse Bio
- Developer Sunbird Bio
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-small cell lung cancer; Solid tumours
Most Recent Events
- 30 Mar 2026 Discontinued - Preclinical for Non-small cell lung cancer (Diagnosis) in USA (unspecified route) (Sunbird Bio website, March 2026)
- 30 Mar 2026 Discontinued for Solid tumours (Diagnosis) in USA (unspecified route) (Sunbird Bio website, March 2026)
- 28 Feb 2025 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer(Diagnosis) in USA